- Home
- TIL vs MCRB Comparison
TIL vs MCRB Comparison
Compare TIL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | MCRB |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 47.4M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TIL | MCRB |
|---|---|---|
| Price | $7.40 | $4.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $125.00 | $14.00 |
| AVG Volume (30 Days) | 8.0K | ★ 53.1K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.67 | $4.44 |
| 52 Week High | $33.83 | $29.98 |
Technical Indicators
Market Signals| Indicator | TIL | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 34.16 |
| Support Level | $6.91 | N/A |
| Resistance Level | $7.50 | $5.65 |
| Average True Range (ATR) | 0.19 | 0.35 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 85.35 | 0.00 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.